WO2002101057A1 - Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur - Google Patents

Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur Download PDF

Info

Publication number
WO2002101057A1
WO2002101057A1 PCT/JP2002/005225 JP0205225W WO02101057A1 WO 2002101057 A1 WO2002101057 A1 WO 2002101057A1 JP 0205225 W JP0205225 W JP 0205225W WO 02101057 A1 WO02101057 A1 WO 02101057A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
embryonic stem
vsv
gene transfer
immunodeficiency virus
Prior art date
Application number
PCT/JP2002/005225
Other languages
English (en)
French (fr)
Other versions
WO2002101057A8 (fr
Inventor
Yutaka Hanazono
Yasuji Ueda
Yasushi Kondo
Yutaka Suzuki
Original Assignee
Dnavec Research Inc.
Tanabe Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc., Tanabe Seiyaku Co., Ltd. filed Critical Dnavec Research Inc.
Priority to US10/479,912 priority Critical patent/US7323337B2/en
Priority to CA002449589A priority patent/CA2449589A1/en
Priority to EP02728191A priority patent/EP1403374A4/en
Priority to JP2003503807A priority patent/JPWO2002101057A1/ja
Priority to AU2002258248A priority patent/AU2002258248C1/en
Priority to KR1020037015930A priority patent/KR100682708B1/ko
Publication of WO2002101057A1 publication Critical patent/WO2002101057A1/ja
Publication of WO2002101057A8 publication Critical patent/WO2002101057A8/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/106—Primate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/JP2002/005225 2001-06-08 2002-05-29 Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur WO2002101057A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/479,912 US7323337B2 (en) 2001-06-08 2002-05-29 Gene transfer into primate embryonic stem cells using VSV-G pseudotyped simian immunodeficiency virus vectors
CA002449589A CA2449589A1 (en) 2001-06-08 2002-05-29 Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector
EP02728191A EP1403374A4 (en) 2001-06-08 2002-05-29 GENE TRANSFER IN EMBRYONIC PRIMATE STEM CELLS WITH THE VSV-G PSEUDOTYPE MONKEY IMMUNITY WEAK VIRUS VECTOR
JP2003503807A JPWO2002101057A1 (ja) 2001-06-08 2002-05-29 Ｖｓｖ−ｇシュードタイプ化サル免疫不全ウイルスベクターを用いた霊長類胚性幹細胞への遺伝子導入
AU2002258248A AU2002258248C1 (en) 2001-06-08 2002-05-29 Gene transfer into primate embryonic stem cells using VSV-G pseudotyped simian immunodeficiency virus vector
KR1020037015930A KR100682708B1 (ko) 2001-06-08 2002-05-29 Ｖｓｖ-ｇ 슈도타입화 원숭이 면역부전 바이러스 벡터를 사용한 영장류 배아 줄기세포로의 유전자 도입

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-174696 2001-06-08
JP2001174696 2001-06-08

Publications (2)

Publication Number Publication Date
WO2002101057A1 true WO2002101057A1 (fr) 2002-12-19
WO2002101057A8 WO2002101057A8 (fr) 2004-02-12

Family

ID=19015942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/005225 WO2002101057A1 (fr) 2001-06-08 2002-05-29 Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur

Country Status (7)

Country Link
US (1) US7323337B2 (ja)
EP (1) EP1403374A4 (ja)
JP (2) JPWO2002101057A1 (ja)
KR (1) KR100682708B1 (ja)
CN (1) CN100557023C (ja)
CA (1) CA2449589A1 (ja)
WO (1) WO2002101057A1 (ja)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087936A1 (ja) * 2004-03-16 2005-09-22 Dnavec Research Inc. 胚性幹細胞に遺伝子を導入する方法
WO2006090697A1 (ja) * 2005-02-23 2006-08-31 Dnavec Corporation Pedfおよびfgf2を含む眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬
WO2007049749A1 (ja) 2005-10-28 2007-05-03 Dnavec Corporation 血液凝固異常の治療方法
US8278284B2 (en) 2005-02-23 2012-10-02 Masanori Miyazaki Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors
WO2013168403A1 (ja) 2012-05-08 2013-11-14 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
WO2014208053A1 (ja) 2013-06-28 2014-12-31 株式会社大塚製薬工場 トレハロース及びデキストラン含有哺乳動物細胞移植用溶液
EP2993235A1 (en) 2005-10-28 2016-03-09 ID Pharma Co., Ltd. Gene transfer into airway epithelial stem cell by using simian lentiviral vector pseudotyped with sendai rna virus spike protein
WO2018005975A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
WO2018084228A1 (ja) 2016-11-04 2018-05-11 国立大学法人東京大学 動物細胞又は動物組織の凍結保存用溶液、凍結物、及び凍結保存方法
WO2018097253A1 (ja) 2016-11-25 2018-05-31 国立研究開発法人理化学研究所 移植用細胞集団及びその製造方法
WO2018110159A1 (ja) 2016-12-14 2018-06-21 株式会社大塚製薬工場 哺乳動物細胞凍結保存液
WO2018164240A1 (ja) 2017-03-08 2018-09-13 大日本住友製薬株式会社 網膜色素上皮細胞の製造方法
WO2019017491A1 (ja) 2017-07-20 2019-01-24 国立研究開発法人理化学研究所 神経組織の保存方法
WO2019017492A1 (ja) 2017-07-20 2019-01-24 国立研究開発法人理化学研究所 連続的な上皮を含む網膜組織の成熟化方法
WO2019050015A1 (ja) 2017-09-08 2019-03-14 国立研究開発法人理化学研究所 網膜組織を含む細胞凝集体及びその製造方法
WO2019054514A1 (ja) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 網膜組織の製造方法
WO2019054515A1 (ja) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法
WO2019103125A1 (ja) 2017-11-24 2019-05-31 住友化学株式会社 神経系細胞又は神経組織と非神経上皮組織とを含む細胞塊の製造方法及びその細胞塊
WO2019103129A1 (ja) 2017-11-24 2019-05-31 住友化学株式会社 下垂体組織を含む細胞塊の製造方法及びその細胞塊
WO2019160148A1 (ja) 2018-02-19 2019-08-22 大日本住友製薬株式会社 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
WO2020039732A1 (ja) 2018-08-24 2020-02-27 住友化学株式会社 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法
WO2020066991A1 (ja) 2018-09-28 2020-04-02 株式会社大塚製薬工場 アカルボース又はスタキオースを含む哺乳動物細胞保存用液
WO2020100481A1 (ja) 2018-11-15 2020-05-22 Jsr株式会社 脳オルガノイドの製造方法
WO2020130068A1 (ja) 2018-12-20 2020-06-25 住友化学株式会社 胚型赤芽球を含む細胞集団及びその製造方法、細胞培養組成物並びに化合物試験法
WO2020138430A1 (ja) 2018-12-28 2020-07-02 国立研究開発法人理化学研究所 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬
WO2020184720A1 (ja) 2019-03-13 2020-09-17 大日本住友製薬株式会社 移植用神経網膜の品質を評価する方法及び移植用神経網膜シート
WO2020218461A1 (ja) 2019-04-26 2020-10-29 株式会社大塚製薬工場 トレハロースを含む哺乳動物細胞保存用液
WO2020218480A1 (ja) 2019-04-26 2020-10-29 国立研究開発法人理化学研究所 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法
WO2021045217A1 (ja) 2019-09-06 2021-03-11 学校法人慶應義塾 グリア前駆細胞を含む細胞凝集体の製造方法
WO2021100830A1 (ja) 2019-11-20 2021-05-27 大日本住友製薬株式会社 細胞凝集体の凍結方法
WO2021100829A1 (ja) 2019-11-20 2021-05-27 大日本住友製薬株式会社 神経系細胞の凍結方法
EP3868873A1 (en) 2014-10-24 2021-08-25 Sumitomo Dainippon Pharma Co., Ltd. Production method for retinal tissue
WO2022054925A1 (ja) 2020-09-11 2022-03-17 国立研究開発法人理化学研究所 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法
WO2022054924A1 (ja) 2020-09-11 2022-03-17 大日本住友製薬株式会社 移植用組織のための媒体
WO2022079322A1 (en) 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
WO2022191216A1 (ja) 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
EP4092109A1 (en) 2015-09-08 2022-11-23 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
WO2022265086A1 (ja) 2021-06-17 2022-12-22 国立大学法人京都大学 ヒト多能性幹細胞由来大脳皮質細胞製剤の製造方法
WO2023054396A1 (ja) 2021-09-30 2023-04-06 住友化学株式会社 下垂体組織を含む細胞集団の製造方法及びその細胞集団
WO2023054395A1 (ja) 2021-09-30 2023-04-06 住友ファーマ株式会社 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003056019A1 (en) * 2001-12-24 2003-07-10 Es Cell International Pte Ltd Method of transducing es cells
WO2007014282A2 (en) * 2005-07-26 2007-02-01 Whitehead Institute For Biomedical Research Transfection method and uses related thereto
MX342449B (es) 2007-08-03 2016-09-29 Pasteur Institut Vectores de transferencia de gen lentiviral y sus aplicaciones medicinales.
CN101550406B (zh) * 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
SI2456786T2 (sl) * 2009-07-24 2017-08-31 Immune Design Corp. Lentiviralni vektorji psevdo-tipizirani z glikoproteinom ovojnice virusa Sindbis
BR112012020257A8 (pt) * 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
JP5784296B2 (ja) * 2010-10-01 2015-09-24 学校法人 創価大学 神経細胞の製造方法及び神経細胞分化促進剤
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2014200659A1 (en) 2013-06-11 2014-12-18 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323031B1 (en) * 1999-03-05 2001-11-27 Bundesrepublik Deutschland Letztvertreten Durch Den Prasidenten Des Paul-Elrich-Instituts Prof. Dr. R. Kruth Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5576201A (en) * 1994-01-14 1996-11-19 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
JP5014535B2 (ja) 2000-06-15 2012-08-29 田辺三菱製薬株式会社 カニクイザル由来胚性幹細胞

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323031B1 (en) * 1999-03-05 2001-11-27 Bundesrepublik Deutschland Letztvertreten Durch Den Prasidenten Des Paul-Elrich-Instituts Prof. Dr. R. Kruth Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ASANO T. ET AL.: "Highly efficient gene transfer into primate embryonic stem cell with a simian lentivirus vector", MOL. THER., vol. 6, no. 2, August 2002 (2002-08-01), pages 162, XP002956700 *
HAMAGUCHI I. ET AL.: "Lentivirus vector gene expressiobn during ES cell-derived hematopoietic development in vitro", J. VIROL., vol. 74, no. 22, November 2000 (2000-11-01), pages 10778 - 10784, XP001037835 *
HANAZONO Y. ET AL.: "Highly efficient gene transfer into cynomolgus monkey embryonic stem cells with a simian lentivirus vector", BLOOD, vol. 98, no. 11, PART 1, November 2001 (2001-11-01), pages 746A, XP002957101 *
LIU M.L. ET AL.: "Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein(VSV-G)-moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer", J. VIROL., vol. 70, no. 4, April 1996 (1996-04-01), pages 2497 - 2502, XP002957102 *
MANGEOT P.E. ET AL.: "Development of minimal lentivirus vectors derived from simian immunodeficiency virus(SIVmac251) and their use for gene transfer into human dendritic cells", J. VIROL., vol. 74, no. 18, September 2000 (2000-09-01), pages 8307 - 8315, XP000943677 *
NAKAJIMA T. ET AL.: "Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system", HUM. GENE THER., vol. 11, no. 13, September 2000 (2000-09-01), pages 1863 - 1874, XP001033905 *
SCHNELL T. ET AL.: "Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus", HUM. GENE THER., vol. 11, February 2000 (2000-02-01), pages 439 - 447, XP000974687 *
See also references of EP1403374A4 *
THOMSON J.A. ET AL.: "Isolation of a primate embryonic stem cell line", PROC. NATL. ACAD. SCI. USA, vol. 92, August 1995 (1995-08-01), pages 7844 - 7848, XP000604992 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087936A1 (ja) * 2004-03-16 2005-09-22 Dnavec Research Inc. 胚性幹細胞に遺伝子を導入する方法
WO2006090697A1 (ja) * 2005-02-23 2006-08-31 Dnavec Corporation Pedfおよびfgf2を含む眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬
JP4971974B2 (ja) * 2005-02-23 2012-07-11 ディナベック株式会社 Ｐｅｄｆおよびｆｇｆ２を含む眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬
US8278284B2 (en) 2005-02-23 2012-10-02 Masanori Miyazaki Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors
WO2007049749A1 (ja) 2005-10-28 2007-05-03 Dnavec Corporation 血液凝固異常の治療方法
US10017784B2 (en) 2005-10-28 2018-07-10 Id Pharma Co., Ltd. Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein
EP2993235A1 (en) 2005-10-28 2016-03-09 ID Pharma Co., Ltd. Gene transfer into airway epithelial stem cell by using simian lentiviral vector pseudotyped with sendai rna virus spike protein
WO2013168403A1 (ja) 2012-05-08 2013-11-14 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
WO2014208053A1 (ja) 2013-06-28 2014-12-31 株式会社大塚製薬工場 トレハロース及びデキストラン含有哺乳動物細胞移植用溶液
EP3868873A1 (en) 2014-10-24 2021-08-25 Sumitomo Dainippon Pharma Co., Ltd. Production method for retinal tissue
EP4092109A1 (en) 2015-09-08 2022-11-23 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
WO2018005975A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
WO2018084228A1 (ja) 2016-11-04 2018-05-11 国立大学法人東京大学 動物細胞又は動物組織の凍結保存用溶液、凍結物、及び凍結保存方法
WO2018097253A1 (ja) 2016-11-25 2018-05-31 国立研究開発法人理化学研究所 移植用細胞集団及びその製造方法
WO2018110159A1 (ja) 2016-12-14 2018-06-21 株式会社大塚製薬工場 哺乳動物細胞凍結保存液
WO2018164240A1 (ja) 2017-03-08 2018-09-13 大日本住友製薬株式会社 網膜色素上皮細胞の製造方法
WO2019017491A1 (ja) 2017-07-20 2019-01-24 国立研究開発法人理化学研究所 神経組織の保存方法
WO2019017492A1 (ja) 2017-07-20 2019-01-24 国立研究開発法人理化学研究所 連続的な上皮を含む網膜組織の成熟化方法
WO2019050015A1 (ja) 2017-09-08 2019-03-14 国立研究開発法人理化学研究所 網膜組織を含む細胞凝集体及びその製造方法
WO2019054514A1 (ja) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 網膜組織の製造方法
WO2019054515A1 (ja) 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法
WO2019103129A1 (ja) 2017-11-24 2019-05-31 住友化学株式会社 下垂体組織を含む細胞塊の製造方法及びその細胞塊
WO2019103125A1 (ja) 2017-11-24 2019-05-31 住友化学株式会社 神経系細胞又は神経組織と非神経上皮組織とを含む細胞塊の製造方法及びその細胞塊
WO2019160148A1 (ja) 2018-02-19 2019-08-22 大日本住友製薬株式会社 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
WO2020039732A1 (ja) 2018-08-24 2020-02-27 住友化学株式会社 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法
WO2020066991A1 (ja) 2018-09-28 2020-04-02 株式会社大塚製薬工場 アカルボース又はスタキオースを含む哺乳動物細胞保存用液
WO2020100481A1 (ja) 2018-11-15 2020-05-22 Jsr株式会社 脳オルガノイドの製造方法
WO2020130068A1 (ja) 2018-12-20 2020-06-25 住友化学株式会社 胚型赤芽球を含む細胞集団及びその製造方法、細胞培養組成物並びに化合物試験法
WO2020138430A1 (ja) 2018-12-28 2020-07-02 国立研究開発法人理化学研究所 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬
WO2020184720A1 (ja) 2019-03-13 2020-09-17 大日本住友製薬株式会社 移植用神経網膜の品質を評価する方法及び移植用神経網膜シート
WO2020218461A1 (ja) 2019-04-26 2020-10-29 株式会社大塚製薬工場 トレハロースを含む哺乳動物細胞保存用液
WO2020218480A1 (ja) 2019-04-26 2020-10-29 国立研究開発法人理化学研究所 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法
WO2021045217A1 (ja) 2019-09-06 2021-03-11 学校法人慶應義塾 グリア前駆細胞を含む細胞凝集体の製造方法
WO2021100829A1 (ja) 2019-11-20 2021-05-27 大日本住友製薬株式会社 神経系細胞の凍結方法
WO2021100830A1 (ja) 2019-11-20 2021-05-27 大日本住友製薬株式会社 細胞凝集体の凍結方法
WO2022054925A1 (ja) 2020-09-11 2022-03-17 国立研究開発法人理化学研究所 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法
WO2022054924A1 (ja) 2020-09-11 2022-03-17 大日本住友製薬株式会社 移植用組織のための媒体
WO2022079322A1 (en) 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
WO2022191216A1 (ja) 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
WO2022265086A1 (ja) 2021-06-17 2022-12-22 国立大学法人京都大学 ヒト多能性幹細胞由来大脳皮質細胞製剤の製造方法
WO2023054396A1 (ja) 2021-09-30 2023-04-06 住友化学株式会社 下垂体組織を含む細胞集団の製造方法及びその細胞集団
WO2023054395A1 (ja) 2021-09-30 2023-04-06 住友ファーマ株式会社 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法

Also Published As

Publication number Publication date
US20040234948A1 (en) 2004-11-25
EP1403374A1 (en) 2004-03-31
AU2002258248B2 (en) 2006-08-17
CN1571844A (zh) 2005-01-26
CN100557023C (zh) 2009-11-04
WO2002101057A8 (fr) 2004-02-12
EP1403374A4 (en) 2004-07-21
AU2002258248B8 (en) 2006-11-23
JPWO2002101057A1 (ja) 2004-09-24
CA2449589A1 (en) 2002-12-19
KR100682708B1 (ko) 2007-02-15
JP2008119006A (ja) 2008-05-29
KR20040003053A (ko) 2004-01-07
US7323337B2 (en) 2008-01-29

Similar Documents

Publication Publication Date Title
WO2002101057A8 (fr) Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
EP1291419A4 (en) MEMBRANE PROTEIN WITH HEMAGGLUTENINE ACTIVITY PAUSED RETROVIRUS VECTOR OF PSEUDOTYPS
DK1224314T3 (da) Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
GB2405406B (en) Viral vectors
AU2234995A (en) Feline immunodeficiency virus vaccine
UA85536C2 (en) Viral antigens
EP1006196A3 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
CA2222769A1 (en) Primers for the detection of hiv-1
RU98100921A (ru) Праймеры для обнаружения вич-1
WO2002038792A3 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
WO2003054160A3 (en) Cell lines with latent immunodeficiency virus and methods of use thereof
AU5322800A (en) Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
WO2003095971A3 (en) Posh nucleic acids, polypeptides and related methods
DK1108786T3 (da) Hidtil ukendt kollektin
USD470784S1 (en) Scale
WO2002004595A3 (en) Production of chimeric human papillomavirus
DK631387A (da) Virusvektor
USD470783S1 (en) Scale
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
WO2000075352A3 (en) Hcv/bvdv chimeric genomes and uses thereof
CA2435323A1 (en) Dna sequence of the enzyme phospholipase a1 of ciliate tetrahymena, and the use of the same
AU4395599A (en) (-)-strand rna virus vector for nerve cell

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003503807

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002258248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2449589

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037015930

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002728191

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028155548

Country of ref document: CN

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWP Wipo information: published in national office

Ref document number: 2002728191

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10479912

Country of ref document: US